Jacopo Peccatori

Dr. Jacopo Peccatori


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
RBRosa Bacchetta
Rosa Bacchetta
BLBarbarella Lucarelli
Barbarella Lucarelli
CSClaudia Sartirana
Claudia Sartirana
SGSilvia Gregori
Silvia Gregori
MSMaria T. Lupo Stanghellini
Maria T. Lupo Stanghellini
MRMaria-Grazia Roncarolo
Maria-Grazia Roncarolo
T-cell therapy after hematopoietic stem cell transplantation (HSCT) has been used alone or in combination with immunosuppression to cure hematologic malignancies and to prevent recurrence. Here, we describe the outcome of patients with high-risk/advanced stage hematologic malignancies, who received T-cell depleted (TCD) haploidentical-HSC transplantation (haplo-HSCT) combined with donor T lymphocytes pretreated with IL-10 (ALT-TEN trial). IL-10 anergized donor T cells (IL-10 DLI) contained T regulatory type 1 (Tr1) cell specific for the, host alloantigens, limiting donor-vs-host reactivity, and memory T cells able to respond to pathogens. IL-10 DLI were infused in 12 patients with the goal of improving immune-reconstitution after haplo-HSCT without increasing the risk of GvHD. IL-10 DLI led to fast immune-reconstitution in five patients. In four out of the five patients, total T-cell counts, TCR-Vβ repertoire and T-cell functions progressively normalized after IL-10 DLI. These four patients are alive, in complete disease remission and immune suppression-free at 7.2 years (median follow-up) after haplo-HSCT. Transient GvHD was observed in the immune reconstituted patients, despite persistent host-specific hypo-responsiveness of donor T cells in vitro and enrichment of cells with Tr1- specific biomarkers in vivo. Gene expression profiles of immune-reconstituted patients showed a common signature of tolerance. This study provides the first indication of the feasibility of Tr1 cell-based therapy and paves the way for the use of these Tr1 cells as adjuvant treatment for malignancies and immune-mediated disorders.

15 December 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
ICIrene Cassaniti
Irene Cassaniti
ACAnna Amelia Colombo
Anna Amelia Colombo
PBPaolo Bernasconi
Paolo Bernasconi
MMMichele Malagola
Michele Malagola
DRDomenico Russo
Domenico Russo
Fausto BaldantiFausto Baldanti
Fausto Baldanti
Letermovir (LMV) inhibits HCMV replication by binding to components of the HCMV terminase complex showing a potential role in prevention of HCMV‐related complications in allogenic hematopoietic stem cell transplant recipients (allo‐HSCTRs). However, little is known about breakthrough HCMV infection and the relevance of HCMV DNAemia during prophylaxis. We reported the results of a multicenter prospective study involving five Italian centers in the management of HCMV DNAemia in 75 adult HCMV‐seropositive allo‐HSCTRs undergoing LMV prophylaxis. The aim of the present study was to characterize the presence of real HCMV reactivation during LMV prophylaxis. Then, the presence of circulating infectious HCMV particles was determined by virus isolation and degradation of free‐floating viral DNA. This report provide the first evidence that during LMV prophylaxis the clinical relevance of HCMV DNAemia should be critically considered.

13 June 2024 in Blood
Verified
Journal Article
Closed access
PDF file
JSJaime Sanz
Jaime Sanz
MLMyriam Labopin
Myriam Labopin
GCGoda Choi
Goda Choi
AKAlexander Kulagin
Alexander Kulagin
JPJacopo Peccatori
Jacopo Peccatori
FCFabio Ciceri
Fabio Ciceri
There is a paucity of information on how to select the most appropriate unrelated donor (UD) in hematopoietic stem cell transplantation (HSCT) using posttransplant cyclophosphamide (PTCy). We retrospectively analyzed the characteristics of 10/10 matched UDs (MUDs) and 9/10 mismatched UDs (MMUDs) that may affect transplant outcomes in patients with acute myeloid leukemia (AML) in first or second complete remission (CR1 or CR2). The primary end point was leukemia-free survival (LFS). Overall, 1011 patients were included with a median age of 54 years (range, 18-77). Donors had a median age of 29 years (range, 18-64); 304 (30%) were females, of which 150 (15% of the whole group) were donors to male recipients, and 621 (61%) were MUDs; 522 (52%) had negative cytomegalovirus (CMV-neg) serostatus, of which 189 (19%) were used for CMV-neg recipients. Donor age older than 30 years had a negative impact on relapse (hazard ratio [HR], 1.38; 95% confidence interval [CI], 1.06-1.8), LFS (HR, 1.4; 95% CI, 1.12-1.74), overall survival (HR 1.45; 95% CI, 1.14-1.85) and graft-versus-host disease (GVHD) free, relapse-free survival (HR, 1.29; 95% CI, 1.07-1.56). In addition, CMV-neg donors for CMV-neg recipients were associated with improved LFS (HR, 0.74; 95% CI, 0.55-0.99). The use of MMUD and female donors for male recipients did not significantly impact any transplant outcomes. For patients undergoing HSCT from a UD with PTCy for AML, donor age <30 years significantly improves survival. In this context, donor age might be prioritized over HLA match considerations. In addition, CMV-neg donors are preferable for CMV-neg recipients. However, further research is needed to validate and refine these recommendations.

17 May 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
FLFrancesca Lorentino
Francesca Lorentino
EXElisabetta Xue
Elisabetta Xue
SMSara Mastaglio
Sara Mastaglio
FGFabio Giglio
Fabio Giglio
DCDaniela Clerici
Daniela Clerici
MLMaria Teresa Lupo-Stanghellini
Maria Teresa Lupo-Stanghellini
Francesca Lorentino, Elisabetta Xue, Sara Mastaglio, Fabio Giglio, Daniela Clerici, Francesca Farina, Simona Piemontese, Alessandro Bruno, Lorenzo Lazzari, Anna

19 February 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EXElisabetta Xue
Elisabetta Xue
FLFrancesca Lorentino
Francesca Lorentino
MSMaria Teresa Lupo Stanghellini
Maria Teresa Lupo Stanghellini
FGFabio Giglio
Fabio Giglio
SPSimona Piemontese
Simona Piemontese
RGRaffaella Greco
Raffaella Greco
Correlation between risk of graft-versus-host disease (GvHD) and CD3+ counts within the peripheral blood stem cell graft has recently been reported in the setting of post-transplant cyclophosphamide (PT-Cy). We aimed to investigate the benefit of the addition of a single dose of anti-T lymphocyte globulin (ATLG 5 mg/kg) to PT-Cy in this setting. Starting in 2019, all patients receiving PBSC transplant containing CD3+ counts above 300 × 106/kg (study group) received a post-transplant dose of ATLG in addition to standard PT-Cy. The study was designed as a real-life analysis and included all consecutive Hematopoietic Stem Cell Transplantation (HSCT) recipients according to the above-mentioned inclusion criterion (n = 21), excluding cord blood and bone marrow donors. Using a 1:2 matched-pair analysis, we compared the outcomes with a historical population who received PT-Cy only (control group). We found a delayed platelet engraftment (29% vs. 45% at 30 days, p = 0.03) and a non-significant trend toward higher risk of poor graft function (29% vs. 19%, p = 0.52). The addition of ATLG impacted long-term immune reconstitution on the CD4+ subsets, but this did not translate into higher rate of relapse or viral infection. Acute GvHD was not significantly impacted, but 1-year cumulative incidence of chronic GvHD was significantly lower in the study group (15% vs. 41%, p = 0.04). Survival outcomes were comparable. In conclusion PT-Cy and ATLG was overall safe and translated into a low rate of chronic GvHD incidence.

24 January 2019 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
LLLorenzo Lazzari
Lorenzo Lazzari
PMPaolo Marra
Paolo Marra
RGRaffaella Greco
Raffaella Greco
FGFabio Giglio
Fabio Giglio
DCDaniela Clerici
Daniela Clerici
JPJacopo Peccatori
Jacopo Peccatori
Hepatic sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is a potentially life-threatening complication that can occur after hematopoietic stem cell transplantation (HSCT). Severe SOS/VOD rapidly evolve in multiple organ dysfunction syndrome (MODS), and it is associated with a mortality rate that exceeds 80% [1, 2]. Ultrasound elastography techniques, including twodimensional shear wave elastography (2D-SWE) and transient elastography (TE), may be useful in allowing early diagnosis, thus enabling a prompt therapeutic intervention before irreversible tissue damage occur [3-5]. Liver stiffness measurement (LSM) was performed using 2D-SWE (ShearWave) and TE (FibroScan). Both of them are user-friendly, accurate, non-invasive techniques, been proven to have a high performance in diagnosing and staging liver fibrosis [6]. These techniques measure shear wave velocity in the liver, which is increased in the context of SOS/VOD because of congestion and portal hypertension [7]. Liver stiffness is expressed as a velocity which is converted in kiloPascals (kPa) through the Young modulus. Normal values range respectively from 2.6 to 6.2 kPa for 2D-SWE, and from 3.9 to 7.1 kPa for TE [8, 9]. According to guidelines, a minimum of three measurements for 2D-SWE and ten measurements for TE are required, and results are considered reliable when the interquartile range (IQR)/ median ratio is lower than 30%. SOS/VOD diagnosis was made according to the European society of Bone and Marrow Transplantation (EBMT) criteria [10].